Medical device experts said they believe it was the first time a
manufacturer had issued such a warning to patients about a cyber
vulnerability, a hot topic in the industry following revelations
last month about possible bugs in pacemakers and defibrillators.
J&J executives told Reuters they knew of no examples of attempted
hacking attacks on the device, the J&J Animas OneTouch Ping insulin
pump. The company is nonetheless warning customers and providing
advice on how to fix the problem.
"The probability of unauthorized access to the OneTouch Ping system
is extremely low," the company said in letters sent on Monday to
doctors and about 114,000 patients who use the device in the United
States and Canada.
"It would require technical expertise, sophisticated equipment and
proximity to the pump, as the OneTouch Ping system is not connected
to the internet or to any external network."
A copy of the text of the letter was made available to Reuters.
![](http://archives.lincolndailynews.com/2016/Oct/05/images/ads/current/ldn_sda_062409.png)
Insulin pumps are medical devices that patients attach to their
bodies that injects insulin through catheters.
The Animas OneTouch Ping, which was launched in 2008, is sold with a
wireless remote control that patients can use to order the pump to
dose insulin so that they do not need access to the device itself,
which is typically worn under clothing and can be awkward to reach.
Jay Radcliffe, a diabetic and researcher with cyber security firm
Rapid7 Inc, said he had identified ways for a hacker to spoof
communications between the remote control and the OneTouch Ping
insulin pump, potentially forcing it to deliver unauthorized insulin
injections.
The system is vulnerable because those communications are not
encrypted, or scrambled, to prevent hackers from gaining access to
the device, said Radcliffe, who reported vulnerabilities in the pump
to J&J in April and published them on the Rapid7 blog on Tuesday.
(http://bit.ly/2dOUm0e)
J&J executives said they worked on the security issues with
Radcliffe.
Dosing a patient with too much insulin could cause hypoglycemia, or
low blood sugar, which in extreme cases can be life threatening,
said Brian Levy, chief medical officer with J&J's diabetes unit.
Company technicians were able to replicate Radcliffe's findings,
confirming that a hacker could order the pump to dose insulin from a
distance of up to 25 feet, Levy said. He said such attacks are
difficult to pull off because they require specialized technical
expertise and sophisticated equipment.
"We believe the OneTouch Ping system is safe and reliable. We urge
patients to stay on the product," Levy said.
J&J's letter said that if patients were concerned, they could take
several steps to thwart potential attacks. They include
discontinuing use of a wireless remote control and programming the
pump to limit the maximum insulin dose.
Radcliffe said he believed that OneTouch Ping users would be safe if
they followed the steps outlined in the letters from J&J.
[to top of second column] |
![](http://archives.lincolndailynews.com/2016/Aug/26/images/ads/current/rohlfs_lda_051513.png)
"They can give peace of mind to the patient or parent of a child
using the device," he said.
FDA GUIDANCE ON MEDICAL DEVICES
In August, a prominent short seller and a cyber security research
firm went public with allegations of potentially life-threatening
cyber vulnerabilities in heart devices from St. Jude Medical Inc.
As its shares tumbled, St. Jude said the allegations were false, and
the U.S. Food and Drug Administration began an investigation.
J&J said before it sent out the letters, it reviewed the matter with
the FDA, which is preparing to issue formal guidance on how medical
device makers should handle reports about cyber vulnerabilities.
An early draft of that guidance, which was released in January for
public comments, called for device makers to work with security
researchers, identify steps to mitigate risks, and provide patients
with information about bugs so they can "make informed decisions"
about device use.
The FDA on Tuesday praised J&J and Rapid7 for their work in
discovering, finding ways to mitigate and disclosing the
vulnerability.
"This is the proactive behavior the FDA has been looking to see from
the medical device manufacturer and research community and
demonstrates the collaborative manner in which vulnerabilities can
be addressed in a way that best protects patients," the agency said
in a statement.
J&J Chief Information Security Officer Marene Allison said her team
would make sure other J&J products do not have similar bugs.
Radcliffe said he found vulnerabilities in the Animas OneTouch Ping,
but not the Animas Vibe line of insulin pumps.
The FDA has said it knows of no cases where hackers have exploited
cyber vulnerabilities to harm a patient.
![](http://archives.lincolndailynews.com/2016/Oct/05/images/ads/current/mb_heating_quarter_FHI_2016.png)
The agency last year issued multiple warnings about cyber bugs in
infusion pumps from Hospira, which has since been acquired by Pfizer
Inc. (http://reut.rs/2duNuZK)
(Reporting by Jim Finkle; Editing by Jonathan Weber and Grant
McCool)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |